The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study ‍of a type of blood cancer, sending its shares up about 3% in ...

Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

Dr. Lu Xianping was recognised for his leadership in innovative drug development and building a successful biopharma company.